Now live: Pro — the full 13F research suite for serious investorsSee pricing →
CHI Advisors LLC

Q4 2022 · 13F-HR

CHI Advisors LLCholdings as filed

Filed 2023-02-13 · accession 0001085146-23-001058

$375.5M
Reported value
23
Positions
2022-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74349U108PROMETHEUS BIOSCIENCES INC$101.6M27.1%923,800CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$61.3M16.3%3,169,892CommonSOLE
H9060V101VECTIVBIO HLDG AG$47.6M12.7%5,492,893CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$41.2M11.0%2,800,126CommonSOLE
230031106CGEMCULLINAN ONCOLOGY INC$35.0M9.32%3,317,544CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$14.3M3.82%3,473,366CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$14.2M3.79%2,829,712CommonSOLE
49372L100KEZAR LIFE SCIENCES INC$13.3M3.54%1,889,451CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$10.3M2.75%215,059CommonSOLE
68217N105OMEGA THERAPEUTICS INC$6.0M1.61%1,055,882CommonSOLE
75120L100RALLYBIO CORP$4.8M1.27%726,109CommonSOLE
45175G108IKENA ONCOLOGY INC$4.4M1.16%1,637,372CommonSOLE
74019P108PRECISION BIOSCIENCES INC$4.2M1.13%3,549,820CommonSOLE
901384107TSVT*2SEVENTY BIO INC$3.1M0.83%333,252CommonSOLE
68570P101ORCHARD THERAPEUTICS PLC$3.0M0.79%7,987,396CommonSOLE
45790W108INOZYME PHARMA INC$2.3M0.62%2,204,876CommonSOLE
35655L107FREELINE THERAPEUTICS HLDGS$2.3M0.61%4,814,419CommonSOLE
221015100CRVSCORVUS PHARMACEUTICALS INC$2.0M0.54%2,384,402CommonSOLE
3621LQ109GTHXEURG1 THERAPEUTICS INC$1.8M0.48%333,945CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$1.6M0.43%864,822CommonSOLE
68236R103ONCORUS INC$599,6720.16%2,367,436CommonSOLE
25460G716LABDUSDDIREXION SHS ETF TR$431,2500.11%25,000CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$29,2500.01%30,000CALLSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.